中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2011年
11期
1952-1954
,共3页
姜应传%廖乃凯%俞建军%徐月敏
薑應傳%廖迺凱%俞建軍%徐月敏
강응전%료내개%유건군%서월민
过氧化物酶体增殖激活物受体%15-脂氧合酶-2%前列腺癌
過氧化物酶體增殖激活物受體%15-脂氧閤酶-2%前列腺癌
과양화물매체증식격활물수체%15-지양합매-2%전렬선암
PPAR-γ%15-LOX-2%Prostate carcinoma
目的 观察过氧化物酶体增殖激活物受体(PPAR-γ)及15-脂氧合酶-2(15-LOX-2)在前列腺癌中的表达,探讨其意义.方法 采用免疫组织化学方法检测28例前列腺癌组织中PPAR-γ及15-LOX-2蛋白的表达,取26例前列腺增生组织作为对照.结果 PPAR-γ在前列腺癌组表达阳性程度高于前列腺增生组(x2=4.84,P<0.05);15-LOX-2在前列腺癌组表达阳性程度低于前列腺增生组(x2 =9.00,P<0.05).T3期前列腺癌PPAR-γ的表达阳性程度明显高于T2期(H=4.103,P<0.05);T2期与T3期前列腺癌细胞15-LOX-2的表达阳性程度差异无统计学意义(H =0.076,P>0.05).Gleason评分≥7分前列腺癌PPAR-γ的表达阳性程度明显高于Gleason评分<7分(H=5.306,P<0.05);Gleason评分≥7分与Gleason评分<7分前列腺癌15-LOX-2的表达阳性程度差异无统计学意义(H =0.313,P>0.05).结论 PPAR-γ蛋白在前列腺癌组织中高表达,并且与病理分期及Gleason评分有关;15-LOX-2在前列腺癌组织中低表达.它提示PPAR-γ和15-LOX-2与前列腺癌发生与发展有关.
目的 觀察過氧化物酶體增殖激活物受體(PPAR-γ)及15-脂氧閤酶-2(15-LOX-2)在前列腺癌中的錶達,探討其意義.方法 採用免疫組織化學方法檢測28例前列腺癌組織中PPAR-γ及15-LOX-2蛋白的錶達,取26例前列腺增生組織作為對照.結果 PPAR-γ在前列腺癌組錶達暘性程度高于前列腺增生組(x2=4.84,P<0.05);15-LOX-2在前列腺癌組錶達暘性程度低于前列腺增生組(x2 =9.00,P<0.05).T3期前列腺癌PPAR-γ的錶達暘性程度明顯高于T2期(H=4.103,P<0.05);T2期與T3期前列腺癌細胞15-LOX-2的錶達暘性程度差異無統計學意義(H =0.076,P>0.05).Gleason評分≥7分前列腺癌PPAR-γ的錶達暘性程度明顯高于Gleason評分<7分(H=5.306,P<0.05);Gleason評分≥7分與Gleason評分<7分前列腺癌15-LOX-2的錶達暘性程度差異無統計學意義(H =0.313,P>0.05).結論 PPAR-γ蛋白在前列腺癌組織中高錶達,併且與病理分期及Gleason評分有關;15-LOX-2在前列腺癌組織中低錶達.它提示PPAR-γ和15-LOX-2與前列腺癌髮生與髮展有關.
목적 관찰과양화물매체증식격활물수체(PPAR-γ)급15-지양합매-2(15-LOX-2)재전렬선암중적표체,탐토기의의.방법 채용면역조직화학방법검측28례전렬선암조직중PPAR-γ급15-LOX-2단백적표체,취26례전렬선증생조직작위대조.결과 PPAR-γ재전렬선암조표체양성정도고우전렬선증생조(x2=4.84,P<0.05);15-LOX-2재전렬선암조표체양성정도저우전렬선증생조(x2 =9.00,P<0.05).T3기전렬선암PPAR-γ적표체양성정도명현고우T2기(H=4.103,P<0.05);T2기여T3기전렬선암세포15-LOX-2적표체양성정도차이무통계학의의(H =0.076,P>0.05).Gleason평분≥7분전렬선암PPAR-γ적표체양성정도명현고우Gleason평분<7분(H=5.306,P<0.05);Gleason평분≥7분여Gleason평분<7분전렬선암15-LOX-2적표체양성정도차이무통계학의의(H =0.313,P>0.05).결론 PPAR-γ단백재전렬선암조직중고표체,병차여병리분기급Gleason평분유관;15-LOX-2재전렬선암조직중저표체.타제시PPAR-γ화15-LOX-2여전렬선암발생여발전유관.
Objective To investigate the expression of peroxisome proliferator-actived receptor γ (PPAR-γ) and 15-1ipoxygenase-2 (15-LOX-2) in tissues of prostate cancer and benign prostatic hyperplasia (BPH),and evaluate the possible significance.Methods Immunohistochemistry was used to detect the expression of PPAR-γ and 15-LOX-2 in 28 cases of prostate cancer and 26 cases of BPH as controls.Results There was significant difference in the expression of PPAR-γ protein between prostate cancer and BPH (x2 =4.84,P <0.05) and 15-LOX-2 (x2 =9.00,P <0.05).The PPAR-γ expression in T2 stage of prostate cancer was significantly higher than in T3 stage (H =4.103,P <0.05),but there was no significant difference in the 15-LOX-2 expression between T2 stage and T3 stage ( H =0.076,P > 0.05 ).The expression of PPAR-γ in prostate cancer with Gleason ≥ 7 was significantly higher than that with Gleason < 7 (H =5.306,P < 0.05),but there was no significant difference in the 15-LOX-2 expression between Gleason > 7 and Gleason < 7 (H =0.313,P > 0.05 ).Conclusion The PPAR-γprotein expression was increased in prostate cancer and related with pathologic stage and Gleason,and the expression of 15-LOX2 was decreased in prostate cancer,suggesting their contribution to the pathogenesis of prostate cancer.